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ABSTRACT
Our understanding of the role of bone marrow (BM)-
derived cells in cutaneous homeostasis and wound healing
had long been limited to the contribution of inﬂammatory
cells. Recent studies, however, suggest that the BM con-
tributes a signiﬁcant proportion of noninﬂammatory cells
to the skin, which are present primarily in the dermis in
ﬁbroblast-like morphology and in the epidermis in a
keratinocyte phenotype; and the number of these
BM-derived cells increases markedly after wounding.
More recently, several studies indicate that mesenchymal
stem cells derived from the BM could signiﬁcantly impact
wound healing in diabetic and nondiabetic animals,
through cell differentiation and the release of paracrine
factors, implying a profound therapeutic potential. This
review discusses the most recent understanding of the
contribution of BM-derived noninﬂammatory cells to
cutaneous homeostasis and wound healing. STEM CELLS
2010;28:905–915
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INTRODUCTION
Recent studies indicate that cells from the bone marrow (BM)
contribute a signiﬁcant proportion of cells in the skin [1, 2].
The normal skin has long been known to contain BM-derived
cells that are involved in host defense and inﬂammatory proc-
esses, including wound healing. However, recent studies
strongly suggest that the BM contributes not only inﬂamma-
tory cells, but also keratinocytes and ﬁbroblast-shaped cells to
the skin [1–3]. Similar to leukocytes in trafﬁcking, stem/pro-
genitor cells derived from the BM could home to injured tis-
sues and participate in the repair/regeneration [4, 5]. More-
over, culture expanded bone marrow-derived mesenchymal
stem cells (BM-MSCs) have been shown to promote the heal-
ing of diabetic wounds [6, 7], implying a profound therapeutic
potential for skin defects such as chronic wounds and burns.
There are two main branches of stem cells in the BM,
including hematopoietic stem cells (HSCs) and mesenchymal
stem cells (MSCs). Adult BM-derived HSCs have long been
recognized as a precursor to all blood cell lineages including
erythrocytes, platelets, and white blood cells. Additionally,
HSCs may also give rise to ﬁbrocytes [8, 9] and endothelial
progenitor cells (EPCs) [10, 11]. A common feature of hema-
topoietic lineage cells is the expression of the cell-surface
antigen CD45, with the exception of mature red blood cells
and their immediate progenitors. Although some studies sug-
gest that HSCs may also give rise to nonblood cells such as
hepatocytes [12], smooth muscle cells, and cardiac myocytes
[13], subsequent studies suggest that these phenomena may
only represent occasional events [14, 15].
BM-MSCs, which are also referred to as BM mesenchy-
mal stromal cells or marrow stromal cells, are self-renewing
and expandable stem cells [16–18]. Although present as a rare
cell population in the BM, representing about 0.001% to
0.01% of the nucleated cells, about 10-fold less abundant than
HSCs, MSCs are expandable in culture and multipotent, capa-
ble of differentiating into several cell types [17, 18]. To com-
pare and contrast study outcomes from different research
groups, the Mesenchymal and Tissue Stem Cell Committee of
the International Society for Cellular Therapy proposed a
minimal criterion to deﬁne human MSCs. First, MSCs must
be plastic-adherent when maintained in standard culture con-
ditions. Second, MSCs must be lineage-negative and express
CD105, CD73, and CD90. Third, MSCs must differentiate to
at least osteoblasts, adipocytes, and chondroblasts in vitro
[19]. Numerous animal studies suggest that BM-MSCs con-
tribute to the repair/regeneration of a variety of injured tissues
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[22], tendon [23, 24], cartilage [25], and meniscus [26].
BM-DERIVED FIBROBLAST-SHAPED CELLS
IN THE DERMIS
Several recent studies suggest that cells from the BM contrib-
ute to a signiﬁcant proportion of the cells in the skin [1, 2,
27]. In one study, using a chimeric mouse model in which the
BM of C57BL mice was reconstituted with BM stem cells
from transgenic mice expressing enhanced green ﬂuorescent
protein (EGFP), EGFP
þ cells derived from the BM were
found in the normal skin and actively participated in wound
healing. Impressively, as many as 15%–20% of the spindle-
shaped dermal ﬁbroblast-like cells in the noninjured normal
skin were EGFP
þ, suggestive of BM origin, and over two
thirds of them were negative for CD45 [1], implying of non-
hematopoietic cells. Consistent with the above observation, in
another study, using a similar mouse model, green ﬂuorescent
protein
þ (GFP
þ) BM-derived cells accounted for 8.7% of
total ﬁbroblast-shaped cells in the normal skin, and the pro-
portion of GFP
þ ﬁbroblast-shaped cells markedly increased in
ﬁbrotic lesions caused by cancer cell implantation (59.7% 6
16.3%) or wounding (32.2% 6 4.8%). Immunoﬂuorescence
analysis showed that these GFP
þ spindle-shaped BM-derived
cells expressed collagen type I, and only about 50% of them
were also positive for CD45 [27]. Taken together, these stud-
ies suggest that about half of the BM-derived ﬁbroblast-
shaped cells in the skin were of nonhematopoietic lineages,
suggestive of noninﬂammatory cells. This ﬁnding has mark-
edly improved our understanding to the contribution of BM
cells in cutaneous physiology and pathology, and opened a
new avenue to study the mechanisms of cutaneous homeosta-
sis and wound healing.
IDENTITIES OF BM-DERIVED FIBROBLAST-LIKE
CELLS IN THE DERMIS
The identities of BM-derived ﬁbroblast-like cells in normal
skin and in the healing wound remain largely to be deter-
mined. Theoretically, several types of cells derived from the
BM may exhibit spindle-shaped ﬁbroblast-like morphology,
including ﬁbroblasts, MSCs, macrophages, ﬁbrocytes, and
EPCs. Macrophages, ﬁbrocytes, and EPCs are currently con-
sidered to originate from HSCs and hence express CD45.
However, it should be noted that the expression of CD45 in
ﬁbrocytes and EPCs decrease on differentiation or maturation
of the cells, and this makes it difﬁcult to recognize them by
this marker. It is unclear whether ﬁbroblasts with similar
properties to those in the connective tissue exist in the BM as
an independent cell population. Thirty years ago, a population
of ﬁbroblast-like cells were found in the BM, which were ad-
herent to plastic tissue culture dishes and formed colonies in
an alpha medium supplemented with serum. The cells were
negative for coagulation factor VIII but expressed collagen
types I and III and ﬁbronectin, which were also expressed by
dermal ﬁbroblasts. The cells were thus termed BM ﬁbroblasts
[28]. In late last decade, cells derived from the BM with simi-
lar isolation and culture methods as used in the above study
were found to be able to differentiate to osteoblasts, chondro-
cytes, and adipocytes, and were thus named MSCs [17, 18].
Theoretically, MSCs are stem cells with multiple differentia-
tion possibilities whereas ﬁbroblasts are specialized cells and
unable to differentiate into other cell lineages, but both of
them are similar in cell morphology and bear a similar group
of surface markers such as CD90, CD44, CD105, and CD73
[29], which are markers considered typical for MSCs. In our
experience, when murine BM-derived lineage negative adher-
ent cells are culture expanded in a medium (a-minimal essen-
tial medium, a-MEM) supportive to the growth of both MSCs
and dermal ﬁbroblasts, over 95% of such cultured cells are
positive for Sca-1. Sca-1 is a marker expressed in murine
MSCs derived from BM and several other tissues, but is not
expressed in dermal ﬁbroblasts [29], and probably other tissue
ﬁbroblasts as well. Moreover, BM-MSCs and dermal ﬁbro-
blasts are distinctively different in expression of a variety of
cytokines and in wound healing (see more discussion in the
subsequent sections). These data suggest that the vast majority
of ﬁbroblast-like cells in the BM are MSCs, and conventional
ﬁbroblasts are likely not to exist in the BM as an independent
cell population.
As MSCs and ﬁbroblasts are similar in morphology and
express a similar group of surface antigens (Sca-1 is not
expressed in humans), it is difﬁcult to distinguish them in tis-
sues, especially in humans. Collagen type I expression was
considered to be a typical feature of dermal ﬁbroblasts by
some investigators [27]. But other studies have indicated that
it is also expressed in ﬁbrocytes [8, 9], macrophages [30], and
MSCs [1]. One study suggests that BM-MSCs express colla-
gen type III, whereas dermal ﬁbroblasts do not [1]. Collagen
type I is the predominant form of collagen in normal human
skin, and the expression of collagen type III increases mark-
edly early in normal wound healing. Therefore, collagen type
III is considered to be particularly important for wound heal-
ing. Interestingly, a study showed that collagen type III was
produced by cells derived from the BM, but not ﬁbroblasts
residing in the dermis [1], implying an indispensable role for
BM-derived cells in wound healing. Unlike MSCs and ﬁbro-
blasts, BM-derived macrophages and ﬁbrocytes can be distin-
guished from dermal ﬁbroblasts and BM-MSCs by their
expression of CD45, and EPCs can be recognized by their
expression of endothelial lineage markers such as VEGFR2
and CD31 [10, 11] (Table 1). Despite their morphological
similarities, dermal ﬁbroblasts, MSCs, macrophages, ﬁbro-
cytes, and EPCs have exhibited distinctive biological and
physiological activities (Table 1).
MSCS FROM THE SKIN AND OTHER TISSUES
RESEMBLE BM-MSCS
‘‘Mesenchyme’’ designates the developing loose connective
tissue of an embryo, mainly derived from the mesoderm, and
giving rise to a large part of the cells of the connective tissue
in the adult [34]. Many mesenchymal tissues contain commit-
ted lineage-directed mesenchymal precursor cells, which par-
ticipate in local regeneration, such as the satellite cell in skel-
etal muscle or the adipocyte progenitors of adipose tissue.
Uncommitted mesenchymal progenitors, capable of giving
rise to other types of mesenchymal tissue other than the one
they are present in, have also been found in scalp tissue [35],
skeletal muscles [36], bone [37], and adipose tissue [38, 39].
Cultured scalp MSCs expressed a similar group of surface
antigens as BM-MSCs. Moreover, scalp MSCs exhibited simi-
lar differentiation potential along osteogenic, chondrogenic,
and adipogenic lineages, compared with human BM-MSCs
[35]. Analysis of MSCs derived from other non-BM sources
has also revealed a strong intergroup correlation of MSCs as
they all express antigens, which have been considered typical
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spite an inconsistent nomenclature and lack of standardized
protocols for cell isolation and culture [38–42].
CIRCULATING MSCS
One major question arising from the similarity of BM-MSCs
to MSCs isolated from other tissues is whether BM consti-
tutes a source of MSCs capable of participating in the repair
and regeneration of multiple tissues of mesenchymal origin in
the adult organism. Systemic infusion of BM-MSCs in
baboons after lethal total body irradiation results in long-term
engraftment of the cells in multiple organs including the skin,
intestines, liver, lungs, thymus, and kidneys [4], indicating
that BM-MSCs have the ability to trafﬁc and survive in blood
and migrate to injured tissue. Many investigators have
attempted to investigate circulating MSCs. Several recent
studies suggest that there is a subpopulation of cells in the pe-
ripheral blood of mice and humans, which resemble BM-
MSCs. Cells that exhibit similar surface antigen proﬁles and
differentiation potency to BM-MSCs have been consistently
isolated from umbilical cord blood [41, 43, 44], indicating the
existence of circulating MSCs in the fetus. In adults, a puta-
tive circulating MSC population (deﬁned as CD45
–/CD34
–
nucleated cells) has been found in the peripheral blood of
mice [45] and humans [46] by ﬂuorescence-activated cell sort-
ing analysis, which accounted for 2–8% of total nucleated
cells in the peripheral blood [45, 46]. However, isolation and
cultivation of this cell population from the peripheral blood
appears to be a difﬁcult task and is frequently unsuccessful.
MSC-like cells in the peripheral blood were ﬁrst characterized
in 2001 using isolation and culture methods similar to those
used for BM-MSC in four species of adult animals (mouse,
rabbit, guinea pig, and human) [47]. Circulating MSCs were
also found in the peripheral blood of patients receiving granu-
locyte colony-stimulating factor (G-CSF) or granulocyte-mac-
rophage colony-stimulating factor (GM-CSF) treatment [48].
However, other research groups have not consistently been
able to isolate these cells from the peripheral blood [49, 50].
In our experience, using an isolation and culture method simi-
lar to that used for BM-MSC, we would occasionally yield
MSC-like cell colonies from the peripheral blood of adult
mice or rats (unpublished data). Taken together, these studies
suggest that circulating MSCs exist in the fetus and adults,
but the abundance appears to decline markedly after birth.
Notably, improvements in the isolation and culture methods
have been shown to increase the yield of blood borne MSCs
in culture [51]. Therefore, more efﬁcient methods will enable
determination of numerical and functional changes in circulat-
ing MSCs relating to age and disease in the future. It has
been reported that hypoxia causes mobilization of BM-MSCs
to the peripheral blood thus increasing the levels of circulat-
ing MSCs [52]. After wounding of the skin, putative BM-
MSCs in the wound also increased [1, 27]. Therefore, the
number of circulating BM-MSCs was expected to increase
accordingly, but unfortunately this has not been studied.
BM-DERIVED MSCS DIFFERENTIATE INTO
KERATINOCYTES
Recent studies have shown that cells derived from the BM
not only contribute to ﬁbroblast-shaped cells in the dermis but
also cells in the epidermis such as a keratinocyte phenotype
[1–3, 53, 54]. In one study, BM-derived epidermal cells were
found to proliferate in the epidermis and localized to a known
stem cell niche, that is, the CD34-positive bulge region of
hair follicles in mice [3]. However, CD34-positive cells
derived from the BM do not appear to contribute to CD34-
postive stem cells in the bulge region of hair follicles [6].
Although theoretically BM-derived cells can form fusion cells
with keratinocytes, and the event was indeed suggested to
occur in one ex vivo study [55], several recent studies have
Table 1. Properties and activities of dermal ﬁbroblast-like cells
Cell origin
Cell surface markers
Collagen
expression
Activity References CD45 CD34 CD73 CD105 CD90 Coll-I Coll-III
Dermal
ﬁbroblasts
Bone marrow?   þ þ þ þ? Release cytokines and ECM
molecules resulting in scar
healing
6, 29, 31, 32
Mesenchymal
stem cells
Bone marrow   þ þ þ þþ Differentiate into keratino-
cytes; release cytokines
promoting dermal repair/
regeneration
1, 6, 29
Fibrocytes Bone marrow þþ   6 N/T þ þþ Differentiate into myoﬁbro-
blasts; release cytokines
promoting ﬁbrosis
8, 9
Macrophages Bone marrow þ   þ   þþ Phagocytosis; release
cytokines promoting
wound healing
30, 33
Endothelial
progenitor
cells
Bone marrow 6 þ 6 N/T þ N/T N/T N/T Differentiate into endothelial
cells and release
cytokines, maintaining
endothelial integrity
and promoting
neovascularization
10, 11
Abbreviations:  , negative; þ, positive; 6, expression decreases or disappear on cell maturation; ?, controversial; (þ), þ 6, Positive to
weak positive; ECM, extracellular matrix; N/T, not tested; Coll-I, collagen type I.
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ferentiation accounts for the formation of BM-derived kerati-
nocytes in vivo [6, 54, 56]. Using a Cre/lox transgenic mouse
model together with b-galactosidase and EGFP expression,
the classic system to determine cell fusion, BM-derived cells
(including MSCs) were found to differentiate into epithelial
cells in the skin, liver, and lungs without cell fusion [56]. The
BM contains several cell types. To determine which cell type
contributes to keratinocytes, we implanted GFP-expressing
CD34-negative BM-MSCs or CD34-positive HSCs into
wounds and examined the outcome. Our data showed that
BM-MSCs but not HSCs adopted a keratinocyte phenotype,
through cell differentiation [6].
MSCS CONTRIBUTE TO STRUCTURAL
REGENERATION OF THE SKIN
In postpartum humans, injury to the skin and other tissues
heals not by the regeneration of the tissue to the preinjured
form but by the formation of scar tissue. Epidermal appen-
dages that have been lost at the site of damage do not regen-
erate. A major goal of wound healing biology is to understand
how skin can be induced to reconstruct the damaged portions
without scar. Increasing evidence suggest that BM-MSCs con-
tribute to cutaneous regeneration. In our previous study, fol-
lowing i.v. infusion of Flk1-positive BM-MSCs derived from
Balb/C mice (with white hair) and unfractionated BM cells
from female C57BL/6 mice for hematological reconstitution
to lethally irradiated female C57BL mice (with black hair),
the recipients gradually grew white hair. Immunohistochemi-
cal analysis of the skin areas bearing the white hair showed
that follicles with white hair segments contained cells derived
from donor MSCs [2], suggesting that BM-MSCs are signiﬁ-
cantly involved in the regeneration of functional hair follicles.
Irradiation injuries to the skin result in cell death, but the
framework of the cutaneous structure remains, which provides
a scaffold for cutaneous regeneration. The involvement of
BM-MSCs in cutaneous regeneration in excisional wounds,
where the scaffold of the skin is lost along with the cells, has
been addressed in the following studies. When a mixture of
BM cells and embryonic skin cells were applied onto a fresh
excisional wound bed within a wound chamber in nude mice,
hair grew from the wounded areas, and a substantial amount
of donor BM-derived cells were detected in the epidermis,
hair follicles, and sebaceous glands. But when BM cells alone
were transplanted onto the wound within the chamber, cutane-
ous regeneration did not occur [57]. However, when we trans-
planted BM-MSCs in a matrix gel onto excisional wounds
without the chamber, glandular appendage-like structures
largely formed by cells derived from BM-MSC appeared in
the healing wound. These results suggest that BM-MSCs
require the coexistence of skin cells and probably molecules
released by them for differentiation and structural regenera-
tion. This statement is further supported by ex vivo results.
Coculture of irradiation injured keratinocytes with BM-MSCs
signiﬁcantly increased the expression of epithelial marker cy-
tokeratins in BM-MSCs, compared with cocultures with unin-
jured keratinocytes [6]. Moreover, BM-MSCs and keratino-
cyte crosstalk appears also to be necessary for structural
organization of the epidermis. In a previous study by Aoki
et al., where keratinocytes were seeded on the top of a colla-
gen matrix containing BM-MSCs, subcutaneous preadipo-
cytes, or dermal ﬁbroblasts, while all three types of stromal
cells promoted the survival of keratinocytes, only BM-MSCs
promoted the formation of rete ridge-like structure in the epi-
dermis, which extended deeper into the matrix (resembling
the dermis) forming glandular structures [58] (Fig. 1). Inter-
estingly, similar glandular structures were also observed in
our in vivo study in the healing wound, but some of the struc-
tures were formed by cells derived from the transplanted BM-
Figure 1. Bone marrow-derived mesenchymal stem cells (BM-MSCs) in cutaneous regeneration. (A, B): Keratinocytes loaded on a collagen gel
containing BM-MSCs formed rete ridge-like structure, whereas keratinocytes loaded on a collagen gel containing dermal ﬁbroblasts did not.
Images adapted from Aoki et al. [58]. Image courtesy of Molecular Biology of the Cell. (C): BM-MSCs (green) from GFP-expressing mice were
injected around the excisional wound and applied on the wound bed in Matrigel in Balb/C mice. At day 7, some mesenchymal stem cells
(yellow) expressed keratinocyte marker cytokeratins (red) and formed structures similar to those observed in the study of Aoki et al. (A).
Abbreviations: BMSC, bone morrow-derived mesenchymal stem cells; H&E, hematoxylin and eosin stain.
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glands; however, these structures disappeared when the
wound was completely closed [6]. Consistent with our ﬁnd-
ings, epithelial cells derived from endogenous BM cells were
found to appear in the wound transiently during wound heal-
ing [54]. These data suggest that BM may not provide long-
term self-renewal stem cells for dermal keratinocytes. How-
ever, these temporary structures formed by keratinocytes
derived from BM-MSCs may serve as precursors of endoge-
nous permanent cutaneous structures and therefore play a crit-
ical role for cutaneous regeneration.
There are contradictory reports over the incidence of dif-
ferentiation of BM-MSCs into epithelial cells [59, 60]. As dis-
cussed in a recent review by Phinney and Prockop [61], a
large number of variables are likely to contribute to the incon-
sistencies in these observations. With culture methods cur-
rently used by most research groups, BM-MSCs quickly age
during culture expansion [55, 62], and undergo autonomous
differentiation toward osteoblasts [62]. Not surprisingly, a
recent study showed that BM-MSCs released less vascular en-
dothelial growth factor (VEGF) and exhibited decreasing pro-
tective effect to isolated rat hearts with successive passages
[63]. The multipotent differentiation potential of BM-MSCs is
expected to decrease accordingly. Therefore, to improve cur-
rent culture conditions to better retain the primitive properties
of MSCs has become a critical issue to achieve reproducible
results in laboratory research and in clinical therapies in the
future.
CULTURE EXPANDED BM-MSCS ENHANCE
WOUND HEALING
After wounding, a considerable number of BM-derived ﬁbro-
blast-shaped cells are present in the skin, and as the major
ﬁbroblast-shaped cell population in the BM, BM-MSCs are
likely to be the major component. Unlike HSCs, BM-MSCs
can easily be expanded in culture. We and others have shown
that ex vivo expanded BM-MSCs promote wound healing in
several animal studies [29, 64–67] (Table 2). Recent studies
by ourselves and others indicate that the excisional wound
splinting model can greatly restrain local skin contraction in
rodents allowing the wound to heal through granulation and
re-epithelialization, and thus give rise to uniform data [6, 29,
68, 69]. With this model, we have shown that topically
applied allogeneic BM-MSCs can signiﬁcantly enhance
wound healing in diabetic db/db mice and normal mice. BM-
MSC-treated wounds exhibited signiﬁcantly faster wound clo-
sure, with increased re-epithelialization, cellularity, and angio-
genesis. Of note, allogeneic BM-MSCs were much more
potent in promoting wound healing than allogeneic dermal
ﬁbroblasts, the major stromal cell population in the skin [6].
More recently, BM-MSCs have been shown to accelerate
wound healing in diabetic rats [67]. Impressively, allogeneic
BM-MSCs exhibited similar survival, engraftment, and effect
as syngeneic BM-MSCs in promoting wound healing [65, 70].
These data are of particular signiﬁcance in developing MSC-
based therapies, as recent studies have shown that biological
activities and therapeutic potential of BM-MSCs are impaired
in elderly individuals and patients with chronic diseases such
as diabetes [71–75].
In addition to accelerating wound closer, BM-MSCs have
been shown to improve the quality of cutaneous repair. Sys-
temic administration of BM-MSCs signiﬁcantly increased the
wound bursting strength of fascial and cutaneous wounds
[65]. More importantly, BM-MSCs appear to enhance cutane-
ous regeneration. In addition to differentiating into keratino-
cytes and forming appendage-like structures, BM-MSCs in
the wound enhance the proliferation of endogenous keratino-
cytes and increase the number of regenerating appendage-like
structures [6].
Little information is available about the effect of BM-
MSCs in wound healing in humans. In a recent report, ﬁve
patients with acute wounds and eight patients with chronic,
long-standing, nonhealing lower extremity wounds received
treatments with BM-MSCs. Autologous BM-MSCs were cul-
ture expanded and topically applied up to four times to the
wounds in a matrix of ﬁbrin. Subsequent tissue biopsy analy-
sis showed signs of the survival of implanted BM-MSCs and
generation of new elastic ﬁbers in the wounds. A reduction of
chronic wound size was found to be closely associated with
the number of cells applied and no treatment-related adverse
events were observed [7]. Although the results are encourag-
ing, many questions remain, such as the optimal cell number
per treatment, frequency of treatment, appropriate
Table 2. Activities of bone marrow-derived mesenchymal stem cells in wound healing
Activity Evidence and mechanisms Administration approach References
BM-MSCs accelerate wound closure Accelerate wound closure in wild-type and diabetic mice Topical 6
Increase wound-breaking strength Topical; systemic 65, 67
Accelerate re-epithelization Topical 6, 65, 67
BM-MSCs differentiate into
keratinocytes
Keratin 14-expressing BM-MSCs in wounds Systemic 76
Keratins-expressing BM-MSCs in wounds without
evidence of cell fusion.
Topical 6
BM-MSCs form appendages of the skin Topical 6
BM-MSCs promote neovascularization Release proangiogenic cytokines such as VEGF, Ang-1;
promote endothelial migration and proliferation; recruit
EPCs into the wound; increase capillary density.
Topical 6, 67
BM-MSCs promote regeneration of
appendages
Release cytokines such as EGF, KGF to promote prolifer-
ation and migration of keratinocytes; increase numbers
of appendage-like structures in wounds
Topical 6, 29
Inﬂuences of BM-MSCs on
inﬂammatory cells
Release cytokines such as MIP-1 and MCP to recruit
macrophages into wounds
Topical 29
Abbreviations: BM-MSCs, bone marrow-derived mesenchymal stem cells; EGF, epidermal growth factor; EPC, endothelial progenitor cell;
KGF, keratinocyte growth factor; MCP, monocyte chemoattractant protein; MIP-1, macrophage inﬂammatory protein-1; VEGF, vascular
endothelial growth factor.
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the fate of the MSCs in the wound. Of these issues, ECM
molecules used to deliver MSCs should be critical, as the
microenvironment for MSCs to survive in human chronic
wounds is very likely to be worse than that in animal models.
Appropriate ECM molecules will not only promote the sur-
vival of MSCs in the wound but also provide materials
required for wound healing.
PARACRINE FACTORS OF MSCSI NCUTANEOUS
REPAIR/REGENERATION
As stromal cells in the BM, MSCs have been known to sup-
port the survival, growth, and differentiation of HSCs by pro-
viding paracrine factors and ECM molecules. Therefore,
MSCs residing in the skin or recruited into the wound are
likely to play a role in maintaining the structural and func-
tional integrity of the skin through a paracrine mechanism.
Several studies have shown that BM-MSCs secrete a variety
of cytokines [29, 77, 78]. In an antibody-based protein array
analysis of 79 human cytokine including growth factors and
chemokines, BM-MSC-conditioned medium reacted to the
large majority of them [29]. Optimum healing of a wound
requires a well-orchestrated integration of many molecular
events mediated by cytokines. As ﬁbroblasts are a major stro-
mal cell population in the skin and are known to secrete
diverse molecules involved in cutaneous homeostasis and
wound healing [31, 32], it is therefore of great signiﬁcance to
understand what distinctive roles the paracrine molecules of
BM-MSCs play in the skin in contrast to dermal ﬁbroblasts.
As shown in a comparative analysis of BM-MSCs-condi-
tioned medium versus dermal ﬁbroblasts-conditioned
medium, of 81 cytokines analyzed, 31 cytokines were distinc-
tively expressed (Table 3). BM-MSCs secreted signiﬁcantly
larger amounts of several growth factors known to enhance
normal wound healing [31, 79, 80], but signiﬁcantly lower
levels of interleukin-6 (IL-6) and osteoprotegerin than dermal
ﬁbroblasts. Of the differentially expressed growth factors, in-
sulin-like growth factor-1 (IGF-1) is particularly intriguing as
the expression of IGF-1 in BM-MSCs is extremely high and
IGF-1 has recently been shown to play a critical role in the
regeneration of various tissues [81, 82]. Therefore, IGF-1,
along with other differentially expressed cytokines, may be
involved in cutaneous regeneration. In accordance with this
speculation, BM-MSC-conditioned medium signiﬁcantly pro-
moted the proliferation of keratinocyte and endothelial cells
in vitro [6], and BM-MSC-treated wounds contained larger
numbers of skin appendages compared with dermal ﬁbro-
blast-treated wounds [6]. IL-6 has long been known as a
potent proinﬂammatory cytokine [83]. Osteoprotegerin is
involved in bone metabolism [84] and its role in wound heal-
ing remains to be deﬁned. In general, cytokine expression
proﬁling suggests that BM-MSCs secrete higher levels of
cytokines known to enhance cell growth and tissue regenera-
tion, whereas dermal ﬁbroblasts expressed greater amounts of
cytokines known to promote inﬂammation. It is likely that
there are higher levels of circulating and residential MSCs in
the human newborn, which mediate more regeneration after
wounding.
Inﬂammatory cells actively participate in wound healing.
Immediately after injury, the wound is hypoxic, which creates
a chemoattractive environment to circulating inﬂammatory
cells. Speciﬁc types of leukocytes are recruited into the
wound after acute injuries, with neutrophils, monocytes (mac-
rophages), and lymphocytes sequentially dominant in the
wound [31, 85], and disturbances in this orderly procedure
may cause disorders in wound healing. For example, delayed
neutrophil and monocyte inﬁltration but more sustained lym-
phocyte inﬁltration has been considered an important causa-
tive factor of chronic wounds [85, 86]. In addition to ﬁghting
bacteria and cleaning up tissue debris from the wound,
inﬂammatory cells clearly affect the wound healing process
through paracrine cytokines [31, 85]. But recent knockout and
knockdown studies in mice suggest that certain leukocyte lin-
eages are not essential for the healing of cutaneous wounds,
particularly a wound without infection. For instances, loss of
mast cells in the wound speeds wound healing with reduced
Table 3. Differentially expressed paracrine factors in bone
marrow-derived mesenchymal stem cells versus dermal ﬁbroblasts
Paracrine
factors
Dermal
ﬁbroblast BM-MSC
Detection
method
EGF 6 þ ABBPA
IGF-1 þþ þ ABBPA
IGF-1 þ þþþþ ELISA
KGF þþ þ ELISA
Ang þþþ þþþþ ABBPA
OSM þþ þ ABBPA
TPO þþ þ ABBPA; ELISA
VEGF þþ þþþþ ABBPA
PDGF-BB 6 þ ABBPA
Leptin 6 þ ABBPA
BDNF þþ þ ABBPA
FGF-4  þ ABBPA
FGF-6 6 þ ABBPA
FGF-7 6 þ ABBPA
FGF-9 þþ þ ABBPA
Flt-3 ligand 6 þ ABBPA
Fractalkine þþ þ ABBPA
GDNF þþ þ ABBPA
HGF þþ þþþ ABBPA
IGFBP-1 6 þ ABBPA
IGFBP-3 þþ þ ABBPA
IGFBP-4 þþ þ ABBPA
LIF þþ þ ABBPA
GRO þþ þ ABBPA
IL-6 þþþþ þþþ ABBPA
MIP-1a þ þþþþ ELISA
MIP-1b þþ þ ABBPA
MIP-3a 6 þ ABBPA
NAP-2 þþ þ ABBPA
OPTGRN þþþþ þþ ABBPA
TGF-b2 þþ þ ABBPA
TGF-b3 þþ þ ABBPA
Human dermal ﬁbroblast- or BM-MSC-conditioned medium
under hypoxic conditions for 24 hours was analyzed with
ABBPA and ELISA. The intensity of each dot was measured.
‘‘ ’’, not detected; 6, weakly detected; þ to þþþþ, intensity of
positive detection.
Abbreviations: ABBPA, antibody-based protein array; Ang;
angiopoietin; BDNF, brain-derived neurotrophic factor;
BM-MSC, bone marrow-derived mesenchymal stem cell; EGF,
epidermal growth factor; ELISA, enzyme-linked immunosorbent
assay; FGF, ﬁbroblast growth factor; Flt-3 ligand, FMS-related
tyrosine kinase 3 ligand; IL, interleukin; GDNF, glial cell
line-derived neurotrophic factor; GRO, growth-related oncogene;
HGF, hepatocyte growth factor; IGF, insulin-like growth factor;
IGFBP, IGF binding protein; KGF, keratinocyte growth factor;
LIF, leukemia inhibitory factor; MIP, macrophage inﬂammatory
protein; NAP-2, neutrophil-activating peptide; OPTGRN,
osteoprotegrin; OSM, oncostatin M; PDGF-BB, platelet-derived
growth factor-BB; TGF, transforming growth factor; TPO,
thrombopoietin; VEGF, vascular endothelial growth factor.
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healing [87]. BM-MSCs are capable of releasing a large num-
ber of chemokines such as macrophage inﬂammatory protein
(MIP)-1, MIP-1, MIP-2, monocyte chemoattractant protein
(MCP)-5, stromal cell-derived factor (SDF)-1, and G-CSF,
which are known to affect certain inﬂammatory cell lineages.
It is therefore of importance to understand whether transplan-
tation, particularly local application, of BM-MSCs inﬂuences
the inﬂammation process in wound healing. Reduced inﬁltra-
tion of inﬂammatory was found in the infarcted myocardium
receiving local injection of BM-MSCs, which was considered
to contribute to the reduced scarring of the myocardium, but
which population of inﬂammatory cells was affected was not
examined [88]. Analysis of cells per excisional wound indi-
cated that BM-MSC-conditioned medium signiﬁcantly
increased the number of macrophages but unchanged the
amount of granulocytes were found; T-cell levels showed a
trend of modest reduction [6]. The results are consistent with
in vitro data, in which BM-MSC-conditioned medium was
strongly chemoattractive to monocytes (sixfold greater than
dermal ﬁbroblast-conditioned medium) [29]. MIP and MCP
are major chemoattractants for monocytes/macrophages and
play a key role in macrophage inﬁltration during wound heal-
ing [89, 90]. BM-MSCs release several fold greater amounts
of MIP-1 and MCP-5 than dermal ﬁbroblasts [29]. Tissue
macrophages have been known to play a pivotal role in
wound healing [89–92]. These results suggest that BM-MSCs
selectively recruit monocytes into the wound through a
release of chemoattractive cytokines (Fig. 2), implying a sig-
niﬁcant therapeutic value of BM-MSCs in chronic wounds.
Neovascularization is a crucial step in the wound healing
process [31, 79, 93]. Local application of BM-MSCs promotes
neovascularization [6]. Paracrine factors of BM-MSCs appear
to play a major role for the increased angiogenesis. First,
BM-MSCs are capable of releasing high levels of proangio-
genic cytokines such as VEGF-a, IGF-1, platelet-derived
growth factor-BB, and angiopoietin (Ang-1), and increased
amounts of VEGF-a and Ang-1 were detected in wounds
treated with BM-MSCs [29, 66]. Second, BM-MSC-condition
medium enhanced angiogenesis in vitro [6]. Finally, wounds
treated with BM-MSC-conditioned medium had increased
numbers of cells positive for CD34, C-kit, or Flk-1, markers
for endothelial lineage cells, suggesting increased recruitment
of endothelial cells and EPCs into the wound [29] (Fig. 2).
BM-DERIVED EPCSI NWOUND HEALING
EPCs are generally considered to be lineage cells derived
from HSCs in the BM, which express CD34 and certain endo-
thelial lineage markers such as Flk-1 and CD31 on the surface
[94]. Currently, it is understood that circulating EPCs contrib-
ute to a proportion of endothelial cells in adults [10, 95–97].
Recently, it has been found that the release of HSCs from the
BM is under circadian control, with a clear peak of HSC
count in the peripheral blood [98, 99]. A similar circadian
rhythm has been observed with EPCs, and disturbances in this
rhythm in diabetes may be associated with pathogenesis of
retinopathy [100]. These observations have implications with
respect to wound healing. It may be advantageous to schedule
surgeries in at risk patients for the time of day when circulat-
ing EPCs to promote healing are at their maximal levels.
Reduced numbers of circulating EPCs have been found in a
broad spectrum of cardiovascular diseases including coronary
artery diseases [101, 102] and rheumatoid arthritis [103]. In
addition to numerical changes, impaired function of circu-
lating EPCs has been found to be associated with cardio-
vascular diseases and aging [104]. EPCs can be mobilized
into the peripheral blood by cytokines such as stromal cell
derived factor-1 (SDF-1), VEGF, and G-CSF [10, 105,
106], vascular trauma [107], and ischemia [10]. After sys-
temic infusion, EPCs can home to ischemic tissue, where
they enhance neovascularization and improve functional
performance of the organ [10, 96, 97].
Recent studies suggest EPCs play an important role in
wound healing. Transplantation of EPCs enhances wound
healing in mice [108]. Wounds treated with EPCs exhibited
Figure 2. Paracrine effect of Bone marrow-derived mesenchymal stem cells (BM-MSCs) in wound healing. BM-MSCs (green) in a cutaneous
wound release growth factors such as IGF-1, EGF, and KGF to promote the proliferation of keratinocytes, release proangiogenic cytokines such
as VEGF-a and Ang-1 to enhance angiogenesis, release chemokines such as MIP-1 to recruit monocytes into the wound, and release cytokines
such as SDF-1 and G-CSF to recruit EPCs into the wound. Abbreviations: ang-1, angiopoietin-1; EGF, epidermal growth factor; EPC, endothelial
progenitor cell; FB, ﬁbroblast; G-CSF, granulocyte colony-stimulating factor; IGF, insulin-like growth factor; KGF, keratinocyte growth factor;
MIP-1, macrophage inﬂammatory protein-1; MSC, mesenchymal stem cell; SDF1, Stromal cell-derived factor-1; VEGF, vascular endothelial
growth factor.
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spite evidence indicating that EPCs contribute to a certain
portion of normal endothelial cells, recent studies have shown
that direct contribution of endothelial cells may not be a
major mechanism in EPC-mediated enhanced wound healing.
Instead, paracrine factors of EPCs appear to play a central
role [108]. EPCs have been known to release a variety of
growth factors such as VEGF, hepatocyte growth factor,
G-CSF, GM-CSF [109], and PDGF [110]. In a more recent
study, topical application of EPCs to ischemic wounds of dia-
betic mice resulted in accelerated wound closure with
increased angiogenesis in the wound, and the action was abro-
gated by coadministering the Wnt antagonist secreted
frizzled-related protein-1 or neutralizing antibodies against
VEGF-a or IL-8, implying that EPCs stimulate wound healing
by paracrine mechanisms that activate Wnt signaling pathway
in recipients [111]. Consistent with the therapeutic effect of
EPCs on wound healing in animals, reduced numbers and
impaired function of circulating EPCs have been described in
both type 1 and type 2 diabetic patients [112, 113]. EPCs
derived from diabetic mice exhibited impaired vascularization
and wound healing [114]. Moreover, chronic wounds in
patients with diabetes showed reduced chemoattractive ability
to EPCs. Administration of exogenous SDF-1a into the wound
reversed EPC homing into the wound and promoted wound
closure [115].
FIBROCYTES IN WOUND HEALING AND
FIBROSIS
Fibrocytes originate from the BM and are considered to be a
newly identiﬁed leukocyte subpopulation. They constitute
0.1%–0.5% of peripheral blood cells and exhibit both mono-
cyte and ﬁbroblast-like characteristics [116, 117] and are
characterized by the expression of collagen type I, ﬁbronec-
tin, CD11b, CD34, and CD45 but not CD14, CD3, or CD10.
Fibrocytes were initially discovered by their rapid and spe-
ciﬁc recruitment from blood to implanted wound chambers in
mice [118]. Subsequently, they have been found in the pe-
ripheral blood, wound sites, and areas of tissue remodeling
[118].
Numerous ﬁbrotic diseases have been found to be associ-
ated with the presence of ﬁbrocytes in ﬁbrotic tissues includ-
ing renal ﬁbrogenesis [119], liver ﬁbrosis, and bleomycin-
mediated pulmonary ﬁbrosis. They have been reported to con-
tribute to the myoﬁbroblast population in wounds [120]. The
number of ﬁbrocytes has been found to be signiﬁcantly
increased in burn patients (up to 10% of peripheral blood
mononuclear cells) compared with that of normal individuals
(<0.5%). Moreover, increased amounts of ﬁbrocytes were
found in hypertrophic scar tissue located primarily in the
deeper layers of the papillary dermis [121], and were found to
produce more collagen but less collagenase, compared with
ﬁbroblasts in the top layer of the dermis, suggesting a role of
ﬁbroblasts from the deeper layer of dermis in the development
of ﬁbrosis [122]. It is likely that ﬁbrocytes regulate the func-
tion of ﬁbroblasts in the deeper dermis in a paracrine fashion
through cytokine production. It has been shown that ﬁbrocytes
are potent producers of proﬁbrotic cytokines transforming
growth factor-1 and connective tissue growth factor. In addi-
tion, ﬁbrocytes can produce ECM molecules such as type I
and III collagen and ﬁbronectin by themselves [117, 118,
123]. Consistent with these observations, it has been shown
that circulating ﬁbrocytes homed to bleomycin-induced lung
inﬂammation, differentiated into ﬁbroblasts and contributed to
lung ﬁbrosis [8]. Interesting but not surprisingly, systemic
administration of BM-MSCs inhibits bleomycin-induced lung
inﬂammation and collagen deposition [124]. Taken together,
ﬁbrocytes originating from the BM interact with surrounding
cells in the skin and may play a pivotal role in abnormal heal-
ing such as hypertrophic scarring.
CONCLUSIONS
Recent studies suggest that ‘‘ﬁbroblasts’’ in the dermis are
heterogenous in origin and function, and the conventional
understanding of these cells, which is based largely on cell
morphology is inadequate. In addition to ﬁbroblasts that
remain during embryonic development, BM appears to be an
important source that provides ‘‘ﬁbroblasts’’ to the skin in
adults, which may include, but is not limited to, CD45-nega-
tive MSCs, CD45-positive ﬁbrocytes and EPCs. The role of
these newly discovered components of ‘‘ﬁbroblasts’’ in the
dermis are not fully understood. BM-MSCs and EPCs are
thought to enhance cutaneous repair/regeneration and ﬁbro-
cytes appear to cause ﬁbrosis and are probably involved in
hypertrophic scar formation. In the future, the development
of speciﬁc markers to recognize MSCs and ﬁbrocytes in
vivo and animal models deﬁcient for these cells will allow
us to better understand their role in physiology and in
diseases.
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